United States v. Wilbern
6:17-cr-06017
W.D.N.Y.Sep 6, 2019Background
- August 12, 2003: investigators collected four forensic swabs (8.1–8.4) from an umbrella; 8.2 and 8.4 were preserved and later submitted for advanced testing.
- In 2011 OCME quantified and LCN-tested the swabs: Swab 8.2 (88.2 pg) was a mixture with a major contributor profile; Swab 8.4 (15.03 pg) yielded a single‑source profile.
- In 2016 OCME compared those profiles to Defendant Richard Wilbern: OCME concluded Swab 8.2 major contributor and Swab 8.4 were consistent with Wilbern (reported population match probabilities reported by OCME).
- Defendant moved to exclude OCME’s LCN DNA results and demanded a Daubert hearing, challenging OCME validation, LCN reliability (stochastic effects, cycle number), and OCME personnel credibility.
- Government resisted, citing prior judicial endorsements (notably United States v. Morgan) and OCME validation/oversight records; independent testing by Bode failed to develop a profile on a related swab (argued by Defendant but rejected by the Court as speculative).
- Court reviewed extensive filings, prior admissibility rulings, OCME validation materials, and the NY DNA Subcommittee’s response, and denied the motion — holding OCME’s LCN results admissible under Federal Rule of Evidence 702/Daubert.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Admissibility of OCME LCN DNA results under Rule 702/Daubert | LCN results are reliable, grounded in OCME validations and accepted by relevant oversight bodies; prior court decisions support admissibility | LCN is unreliable (stochastic effects, contamination, off‑label PCR cycles); OCME validations inadequate; exclude results or hold Daubert hearing | Denied: Court found relevance and sufficient reliability; LCN testing as applied here meets Rule 702/Daubert |
| Need for a separate Daubert hearing | Not necessary given extensive submissions and existing precedent; court may exercise gatekeeping without extra hearing | Demands a hearing to examine OCME methods, validations, and personnel credibility | Denied: Court reviewed record and precedent and concluded no additional hearing required |
| Sample‑specific concerns (low picogram amount; mixture vs single source) | OCME’s protocols and validation support interpretation; Swab 8.4 was single‑source per OCME | OCME’s finding of single‑source for a ~15 pg sample is unreliable; Bode’s differing result on a related swab undermines OCME | Denied: Court found OCME’s interpretation reliable for these samples; Bode results were not persuasive to exclude OCME evidence |
| Credibility and oversight challenges to OCME (statements by OCME officials, Legal Aid/Defenders allegations) | Oversight reviews (DNA Subcommittee) and accreditation addressed concerns; OCME no longer uses LCN but prior use does not make past results inadmissible | OCME made misleading representations; internal validation gaps and personnel credibility issues undermine admissibility | Denied: Court found DNA Subcommittee’s review and OCME validations sufficient; credibility concerns do not render evidence inadmissible and are for cross‑examination |
Key Cases Cited
- Daubert v. Merrell Dow Pharm., 509 U.S. 579 (1993) (establishes gatekeeping standard for expert evidence admissibility under Rule 702)
- Kumho Tire Co. v. Carmichael, 526 U.S. 137 (1999) (extends Daubert gatekeeping flexibility to all expert testimony)
- Amorgianos v. Nat'l R.R. Passenger Corp., 303 F.3d 256 (2d Cir. 2002) (sets Rule 702 indicia: sufficient facts/data, reliable principles/methods, reliable application)
- United States v. Williams, 506 F.3d 151 (2d Cir. 2007) (emphasizes district court's gatekeeping and permissive standard but warns against rote admission)
- United States v. Morgan, [citation="675 F. App'x 53"] (2d Cir. 2017) (affirming district court admission of OCME LCN results after extensive Daubert analysis)
- United States v. Morrow, 374 F. Supp. 2d 51 (D.D.C. 2005) (recognizes PCR/STR DNA testing generally meets Daubert)